Showing results (131-140 of 399) with videos related to

Sort By:
Pageof 40
Leukemia Research|June 19, 2013
Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)Eyal C Attar, Philip C Amrein, James W Fraser, et al.
The New England Journal of Medicine|June 14, 2016
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic LeukemiaHagop M Kantarjian, Daniel J DeAngelo, Matthias Stelljes, et al.
Blood|September 20, 2021
Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemiaDaniel J DeAngelo, Brian A Jonas, Jane L Liesveld, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 6, 2026
Presenting features and outcomes to standard systemic therapies in patients with MTAP-deleted advanced non-small cell lung cancerJulian Huang, Mihaela Aldea, Kathryn W Miller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2024
Phase I/II Investigator-Initiated Study of Olaparib and Temozolomide in SCLC: Final Analysis and CNS OutcomesCatherine B Meador, Subba R Digumarthy, Beow Y Yeap, et al.
Nature Communications|April 13, 2023
Priming a vascular-selective cytokine response permits CD8+ T-cell entry into tumorsDae Joong Kim, Swetha Anandh, Jamie L Null, et al.
Leukemia Research|June 24, 2011
Outcome of older adults with cytogenetically normal AML (CN-AML) and FLT3 mutationsHarshabad Singh, Salma Asali, Lillian L Werner, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 1, 2019
Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic LeukemiaDavid I Marks, Partow Kebriaei, Matthias Stelljes, et al.
British Journal of Haematology|May 25, 2013
Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosisDaniel J DeAngelo, Ruben A Mesa, Warren Fiskus, et al.
Molecular and Cellular Biology|April 30, 2014
The Pim-1 protein kinase is an important regulator of MET receptor tyrosine kinase levels and signalingBo Cen, Ying Xiong, Jin H Song, et al.
Pageof 40